4.6 Review

Small interfering RNA-based nanotherapeutics for treating skin-related diseases

Journal

EXPERT OPINION ON DRUG DELIVERY
Volume 20, Issue 6, Pages 757-772

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2023.2206646

Keywords

SiRNA; RNAi; skin delivery; topical application; nanoparticle

Ask authors/readers for more resources

The potential of using RNA interference (RNAi) for treating skin disorders is discussed in this review article. The design of siRNA delivery systems and the mechanisms of nanoparticle-mediated siRNA skin penetration are emphasized. Further clinical studies are needed to validate the findings from cellular and animal experiments, and the scalability and reproducibility of nanoparticle products should also be addressed.
IntroductionRNA interference (RNAi) has demonstrated great potential in treating skin-related diseases, as small interfering RNA (siRNA) can efficiently silence specific genes. The design of skin delivery systems for siRNA is important to protect the nucleic acid while facilitating both skin targeting and cellular ingestion. Entrapment of siRNA into nanocarriers can accomplish these aims, contributing to improved targeting, controlled release, and increased transfection.Areas coveredThe siRNA-based nanotherapeutics for treating skin disorders are summarized. First, the mechanisms of RNAi are presented, followed by the introduction of challenges for skin therapy. Then, the different nanoparticle types used for siRNA skin delivery are described. Subsequently, we introduce the mechanisms of how nanoparticles enhance siRNA skin penetration. Finally, the current investigations associated with nanoparticulate siRNA application in skin disease management are reviewed.Expert opinionThe potential application of nanotherapeutic RNAi allows for a novel skin application strategy. Further clinical studies are required to confirm the findings in the cell-based or animal experiments. The capability of large-scale production and reproducibility of nanoparticle products are also critical for translation to commercialization. siRNA delivery by nanocarriers should be optimized to attain cutaneous targeting without the risk of toxicity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available